445303-65-1

Usage

Uses

Used in Organic Synthesis:
2-(3-(difluoroMethyl)-4-fluorophenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a reagent in organic synthesis for its ability to form carbon-carbon bonds through Suzuki-Miyaura cross-coupling reactions. This allows for the creation of a wide range of organic compounds with potential applications in various industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 2-(3-(difluoroMethyl)-4-fluorophenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is used as a key intermediate in the synthesis of new drugs. Its unique structure and reactivity enable the development of innovative drug candidates with potential therapeutic benefits.
Used in Material Science:
2-(3-(difluoroMethyl)-4-fluorophenyl)-4,4,5,5-tetraMethyl-1,3,2-dioxaborolane is also utilized in material science for the development of new materials with unique properties. Its versatility in organic synthesis allows for the creation of materials with tailored characteristics for specific applications, such as in electronics, coatings, or advanced materials.

Upstream product

• 445303-69-5 4-bromo-2-(difluoromethyl)-1-fluorobenzene 
• 73183-34-3 bis(pinacol)diborane 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 749932-17-0 4-bromo-1-(difluoromethyl)-2- fluorobenzene 
• 633327-22-7 5-bromo-2,3-difluorobenzaldehyde 
• 1805422-92-7 5-bromo-1-(difluoromethyl)-2,3-difluorobenzene 

Relevant academic research and scientific papers

SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

PYRIDINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by G

SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B rece

SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.

PYRAZINE CARBAMATES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.

SUBSTITUTED PYRAZOLO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor a

SUBSTITUTED PYRAZOLO-PYRIDINE AMIDES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.

KINASE ANTAGONISTS AND METHODS FOR MAKING AND USING THEM

Disclosed herein are small molecule compounds that are SGK1 antagonists, formulations and pharmaceutical compositions comprising the compounds, and methods of making and using them, for treating, ameliorating, preventing, reversing or slowing the progression of: a cancer, a tumor, a metastasis or a dysplastic or a dysfunctional cell condition responsive to inhibition of a kinase enzyme of the AGC group of kinases including SGK1, by administration of an AGC kinase inhibitor or antagonist.

SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS

Substituted pyrimidine and pyridines as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.